Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Oramed Pharmaceuticals (ORMP) Gross Margin (2016 - 2025)

Oramed Pharmaceuticals filings provide 7 years of Gross Margin readings, the most recent being 0.65% for Q1 2025.

  • Quarterly Gross Margin changed N/A to 0.65% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 0.65% through Dec 2025, changed N/A year-over-year, with the annual reading at 0.65% for FY2025, N/A changed from the prior year.
  • Gross Margin hit 0.65% in Q1 2025 for Oramed Pharmaceuticals, down from 71.51% in the prior quarter.
  • Across five years, Gross Margin topped out at 72.37% in Q1 2023 and bottomed at 0.65% in Q1 2025.
  • Average Gross Margin over 3 years is 38.61%, with a median of 37.87% recorded in 2022.
  • Peak annual rise in Gross Margin hit 6096bps in 2023, while the deepest fall reached 2789bps in 2023.
  • Oramed Pharmaceuticals' Gross Margin stood at 32.11% in 2022, then surged by 123bps to 71.51% in 2023, then crashed by -99bps to 0.65% in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Gross Margin are 0.65% (Q1 2025), 71.51% (Q2 2023), and 72.37% (Q1 2023).